skip to main content
Language:
Search Limited to: Search Limited to: Resource type Show Results with: Show Results with: Search type Index
Result Number Material Type Add to My Shelf Action Record Details and Options
1
5PSQ-149 Durvalumab for the treatment of non-small cell lung cancer: real-world experience
Material Type:
Article
Add to My Research

5PSQ-149 Durvalumab for the treatment of non-small cell lung cancer: real-world experience

European journal of hospital pharmacy. Science and practice, 2022-03, Vol.29 (Suppl 1), p.A164-A165 [Peer Reviewed Journal]

European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;2022 European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 2047-9956 ;EISSN: 2047-9964 ;DOI: 10.1136/ejhpharm-2022-eahp.346

Full text available

2
5PSQ-085 Medication errors and pharmaceutical interventions for drugs administered by feeding tube
Material Type:
Article
Add to My Research

5PSQ-085 Medication errors and pharmaceutical interventions for drugs administered by feeding tube

European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A189-A189 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 2047-9956 ;EISSN: 2047-9964 ;DOI: 10.1136/ejhpharm-2020-eahpconf.402

Full text available

3
4CPS-142 Effectiveness and safety of anti-IL-5 biologic agents in severe eosinophilic asthma
Material Type:
Article
Add to My Research

4CPS-142 Effectiveness and safety of anti-IL-5 biologic agents in severe eosinophilic asthma

European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A114-A115 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 2047-9956 ;EISSN: 2047-9964 ;DOI: 10.1136/ejhpharm-2020-eahpconf.243

Full text available

4
5PSQ-050 Successful desensitisation in a patient with dasatinib hypersensitivity
Material Type:
Article
Add to My Research

5PSQ-050 Successful desensitisation in a patient with dasatinib hypersensitivity

European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A172-A172 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 2047-9956 ;EISSN: 2047-9964 ;DOI: 10.1136/ejhpharm-2020-eahpconf.367

Full text available

5
4CPS-102 Influence of palbociclib toxicity in real world clinical practice
Material Type:
Article
Add to My Research

4CPS-102 Influence of palbociclib toxicity in real world clinical practice

European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A95-A95 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 2047-9956 ;EISSN: 2047-9964 ;DOI: 10.1136/ejhpharm-2020-eahpconf.203

Full text available

6
4CPS-127 Economic impact of intensification regimens in inflammatory bowel disease
Material Type:
Article
Add to My Research

4CPS-127 Economic impact of intensification regimens in inflammatory bowel disease

European journal of hospital pharmacy. Science and practice, 2020-03, Vol.27 (Suppl 1), p.A107-A107 [Peer Reviewed Journal]

Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;2020 Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ. ;ISSN: 2047-9956 ;EISSN: 2047-9964 ;DOI: 10.1136/ejhpharm-2020-eahpconf.228

Full text available

7
4CPS-031 The primary efficacy endpoint for alirocumab, reductions in low-density lipoprotein cholesterol
Material Type:
Article
Add to My Research

4CPS-031 The primary efficacy endpoint for alirocumab, reductions in low-density lipoprotein cholesterol

European journal of hospital pharmacy. Science and practice, 2019-03, Vol.26 (Suppl 1), p.A81-A82 [Peer Reviewed Journal]

2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;2019 2019, Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions ;ISSN: 2047-9956 ;EISSN: 2047-9964 ;DOI: 10.1136/ejhpharm-2019-eahpconf.180

Full text available

Personalize your results

  1. Edit

Refine Search Results

Expand My Results

  1.   

Refine My Results

Creation Date 

From To

Searching Remote Databases, Please Wait